Table 3. Mean costs of healthcare resources associated with benzodiazepine use and cessation.
| Categories of resource use | SIW | SIF | TAU | |||
|---|---|---|---|---|---|---|
| Cost | N | Cost | N | Cost | N | |
| Cost per GP workshop (€) | ||||||
| Balearic Islands | 468 | 3 | 543 | 3 | 0.00 | 3 |
| Catalunya | 466 | 2 | 541 | 2 | 0.00 | 2 |
| Valencia | 462 | 3 | 543 | 3 | 0.00 | 3 |
| Cost of initial visit to the GP by participant | ||||||
| Balearic Islands | 62.00 | 61 | 62.00 | 64 | 0.00 | 62 |
| Catalunya | 40.00 | 60 | 40.00 | 56 | 0.00 | 76 |
| Valencia | 56.39 | 47 | 56.39 | 71 | 0.00 | 35 |
| Cost of follow up visits to the GP by participant | ||||||
| Balearic Islands | 105.54 | 57 | 212.83 | 63 | 114.44 | 59 |
| Catalunya | 96.95 | 59 | 189.09 | 55 | 85.41 | 74 |
| Valencia | 160.89 | 45 | 324.12 | 68 | 98.82 | 34 |
| Cost of benzodiazepine consumed (over time): | ||||||
| Baseline | ||||||
| Alprazolam | 4.50 | 168 | 5.01 | 191 | 3.79 | 173 |
| Diazepam | 2.04 | 168 | 2.63 | 191 | 1.19 | 173 |
| Lormetazepam | 7.29 | 168 | 8.29 | 191 | 7.49 | 173 |
| Lorazepam | 3.04 | 168 | 2.03 | 191 | 4.36 | 173 |
| Zolpidem | 4.00 | 168 | 4.93 | 191 | 5.05 | 173 |
| Other Benzodiazepine * | 5.42 | 168 | 3.63 | 191 | 4.51 | 173 |
| 6 months | ||||||
| Alprazolam | 2.41 | 157 | 2.85 | 186 | 3.54 | 171 |
| Diazepam | 2.18 | 157 | 4.05 | 186 | 1.60 | 171 |
| Lormetazepam | 3.21 | 157 | 2.58 | 186 | 3.23 | 171 |
| Lorazepam | 1.30 | 157 | 1.65 | 186 | 4.41 | 171 |
| Zolpidem | 2.57 | 157 | 2.17 | 186 | 3.93 | 171 |
| Other Benzodiazepine * | 2.90 | 157 | 2.56 | 186 | 5.71 | 171 |
| 12 months | ||||||
| Alprazolam | 2.55 | 168 | 2.64 | 191 | 3.64 | 173 |
| Diazepam | 1.76 | 168 | 2.86 | 191 | 1.98 | 173 |
| Lormetazepam | 3.57 | 168 | 4.52 | 191 | 5.83 | 173 |
| Lorazepam | 1.58 | 168 | 1.50 | 191 | 4.01 | 173 |
| Zolpidem | 2.60 | 168 | 1.41 | 191 | 3.30 | 173 |
| Other Benzodiazepine * | 2.58 | 168 | 2.72 | 191 | 6.02 | 173 |
| Total Cost per Average Patient | 201.05 | 149 | 301.51 | 173 | 83.11 | 152 |
*Total cost only reports specific formulations (over 5% market share) however in analysis specific unit cost applied (Full list of unit cost available on request from the author (see annex)).